Liver, NAFLD and COVID-19

Hoffmann, Carlotta; Gerber, Philipp A.; Cavelti-Weder, Claudia; Licht, Louisa; Kotb, Reham; Dweik, Rania Al; Cherfan, Michelle; Bornstein, Stefan R.; Perakakis, Nikolaos

doi:10.1055/a-1834-9008

Cited by 14 publications

(12 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, other mechanisms such as an increased susceptibility to infections, a reduced immune Response, and an increased risk of coagulation could contribute to a higher risk of severe COVID-19 in people with NAFLD [106].…”

Section: Discussionmentioning

confidence: 99%

Liver injury in COVID-19 patients with non-alcoholic fatty liver disease: an update

Miranda¹,

Garlatti²,

Porto³

et al. 2023

Arch Med Sci Atheroscler Dis

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic has revolutionized the priorities of the medical society worldwide. Although most patients infected with SARS-CoV-2 exhibit respiratory symptoms, other organs may also be involved, including the liver, often resulting in liver injury. Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, and its prevalence is expected to increase together with the epidemics of type 2 diabetes and obesity. Data about liver injury during COVID-19 are numerous, while overviews of this infection in patients with NAFLD, both in terms of respiratory and liver, are emerging. In this review, we summarise the current research focusing on COVID-19 in NAFLD patients and discuss the association between liver injury in COVID-19 subjects and non-alcoholic fatty liver disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Liver injury in COVID-19 patients with non-alcoholic fatty liver disease: an update

Miranda¹,

Garlatti²,

Porto³

et al. 2023

Arch Med Sci Atheroscler Dis

View full text Add to dashboard Cite

show abstract

“…"Cytokine storm" was often observed in severe COVID-19 and could lead to multiple organ failures, including severe liver damage [34,35]. A recent study demonstrated that IL-6 was probably the main cytokine orchestrating this inflammatory response leading to liver damage [36]. Given that systemic inflammatory response syndrome (SIRS) induces inflammation in multiple tissues, including the liver, it is reasonable to assume that it may further aggravate a pre-existing inflammatory state, like the one observed in NASH [37].…”

Section: Discussionmentioning

confidence: 99%

Systems biology approach reveals a common molecular basis for COVID-19 and non-alcoholic fatty liver disease (NAFLD)

et al. 2022

View full text Add to dashboard Cite

Background Patients with non-alcoholic fatty liver disease (NAFLD) may be more susceptible to coronavirus disease 2019 (COVID-19) and even more likely to suffer from severe COVID-19. Whether there is a common molecular pathological basis for COVID-19 and NAFLD remains to be identified. The present study aimed to elucidate the transcriptional alterations shared by COVID-19 and NAFLD and to identify potential compounds targeting both diseases. Methods Differentially expressed genes (DEGs) for COVID-19 and NAFLD were extracted from the GSE147507 and GSE89632 datasets, and common DEGs were identified using the Venn diagram. Subsequently, we constructed a protein–protein interaction (PPI) network based on the common DEGs and extracted hub genes. Then, we performed gene ontology (GO) and pathway analysis of common DEGs. In addition, transcription factors (TFs) and miRNAs regulatory networks were constructed, and drug candidates were identified. Results We identified a total of 62 common DEGs for COVID-19 and NAFLD. The 10 hub genes extracted based on the PPI network were IL6, IL1B, PTGS2, JUN, FOS, ATF3, SOCS3, CSF3, NFKB2, and HBEGF. In addition, we also constructed TFs–DEGs, miRNAs–DEGs, and protein–drug interaction networks, demonstrating the complex regulatory relationships of common DEGs. Conclusion We successfully extracted 10 hub genes that could be used as novel therapeutic targets for COVID-19 and NAFLD. In addition, based on common DEGs, we propose some potential drugs that may benefit patients with COVID-19 and NAFLD.

show abstract

“…[4] Notably, individuals suffering from NAFLD are at higher risk of developing coronavirus disease 2019 (COVID-19). [5,6] Meanwhile, the enhanced physical inactivity, overeating and depression associated with COVID-19 exert adverse effects on NAFLD, ultimately contributing to elevated liver-related mortality. [7] In recent years, increasing efforts have been given towards management of fatty liver diseases using nutraceuticals, over the last decade with obvious increase in research papers from 16 records in 2008 to reach 218 in 2022 as retrieved by searching SCOPUS database for literature using keywords of cereal polyphenols (Appendix A1, Supporting Information, and Figure 1).…”

Section: Introductionmentioning

confidence: 99%

“…[ 4 ] Notably, individuals suffering from NAFLD are at higher risk of developing coronavirus disease 2019 (COVID‐19). [ 5,6 ] Meanwhile, the enhanced physical inactivity, overeating and depression associated with COVID‐19 exert adverse effects on NAFLD, ultimately contributing to elevated liver‐related mortality. [ 7 ]…”

Section: Introductionmentioning

confidence: 99%

Does Flavonoid Supplementation Alleviate Non‐Alcoholic Fatty Liver Disease? A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Li,

Ji,

et al. 2023

Molecular Nutrition Food Res

View full text Add to dashboard Cite

ScopeHigher flavonoid intake is associated with reduced risk of non‐alcoholic fatty liver disease (NAFLD). However, there is a large discrepancy in the effects of flavonoid supplementation on NAFLD. To fill such knowledge gap, we systematically reviewed randomized clinical trials (RCTs) to critically assess flavonoid supplementation effect on liver function, lipid profile, inflammation, and insulin resistance in adults with NAFLD.Methods and resultsA systematic search was conducted from 4 databases from inception until May 2023. Twelve RCTs were included in the final analysis demonstrating beneficial effects of flavonoids on ALT (SMD = −3.59, p = 0.034), AST (SMD = −4.47, p = 0.001), GGT (SMD = −8.70, p = 0.000), CK‐18M30 (SMD = −0.35, p = 0.042), TG (SMD = −0.37, p = 0.001), LDL‐C (SMD = −0.38, p = 0.039), TC (MD = −0.25 mmol/l, p = 0.017), steatosis score (MD = −18.97, p = 0.30), TNF‐α (MD = −0.88, p = 0.000), and NF‐κB (MD = −1.62, p = 0.001).ConclusionThis meta‐analysis suggests that flavonoid alleviates NAFLD through exerting favourable effects on liver function, lipid profile, and inflammation, indicating flavonoid supplementation presents a promising drug regimen for the management of NAFLD and its associated complications.

show abstract

Liver, NAFLD and COVID-19

Cited by 14 publications

References 128 publications

Liver injury in COVID-19 patients with non-alcoholic fatty liver disease: an update

Liver injury in COVID-19 patients with non-alcoholic fatty liver disease: an update

Systems biology approach reveals a common molecular basis for COVID-19 and non-alcoholic fatty liver disease (NAFLD)

Does Flavonoid Supplementation Alleviate Non‐Alcoholic Fatty Liver Disease? A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Contact Info

Product

Resources

About